Over the last 10 years, capex has exceeded depreciation 8 times out of 10, however the accumulated depreciation ratio to gross PPE & leasehold improvements is 59%, when 5 years ago it was 42%. The difference is 17%, which if you multiply by current gross PPE & leases hold improvements, you get 39.56m. To me that sum looks like catch up capex TRS is going to have to spend over the next 5 or so years (if it wishes to restore PPE to more appropriate levels). Its quite a chuck given if you divide it by 5 you get 7.9m which is 21% of the most recent annual EBITDA, & this theoretical cost would roll for 5 years. Of course TRS might decide to maintain PPE & leaseholds at current rates, however surely they cant let it run to 70% or beyond. Depreciation is a real charge.
Morever its alarming TRS capex has so frequently been above its depreciation rate on a yearly basis, yet its core assets are losing value YoY. TRS might be more capital intensive than its historical capex has led to believe.
- Forums
- ASX - By Stock
- TRS
- TRS chart
TRS
the reject shop limited
Add to My Watchlist
0.30%
!
$6.68

TRS chart, page-143
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
$6.68 |
Change
0.020(0.30%) |
Mkt cap ! $249.6M |
Open | High | Low | Value | Volume |
$6.66 | $6.68 | $6.66 | $927.6K | 139.0K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
4 | 48915 | $6.67 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$6.68 | 17411 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 4 | 7.010 |
4 | 21328 | 6.680 |
5 | 53915 | 6.670 |
2 | 8000 | 6.660 |
1 | 10000 | 6.650 |
Price($) | Vol. | No. |
---|---|---|
6.670 | 2829 | 1 |
6.680 | 124414 | 4 |
6.690 | 10737 | 4 |
6.700 | 189343 | 5 |
6.720 | 2976 | 1 |
Last trade - 16.19pm 25/06/2025 (20 minute delay) ? |
Featured News
TRS (ASX) Chart |
The Watchlist
PTX
PRESCIENT THERAPEUTICS LIMITED
James McDonnell, CEO
James McDonnell
CEO
SPONSORED BY The Market Online